上海澳华内镜股份有限公司 简式权益变动报告书 上市公司名称：上海澳华内镜股份有限公司 股份变动性质：被动稀释、股份减少（集中竞价） 签署日期：2025 年 11 月 24 日 股票上市地点：上海证券交易所 股票简称：澳华内镜 股票代码：688212 信息披露义务人 1：顾康 通讯地址：上海市闵行区光中路 133 弄 66 号 信息披露义务人 2：顾小舟 通讯地址：上海市闵行区光中路 133 弄 66 号 信息披露义务人 3：上海小洲光电科技有限公司 通讯地址：上海市闵行区紫星路 588 号 2 幢 3 楼 330 室 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券公司信息 披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准则 15 号》"）及 相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》、《收购办法》、《准则 15 号》的规定，本报告书已全面 披露 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-072 上海澳华内镜股份有限公司 关于控股股东、实际控制人权益变动触及 5%整数倍刻 度的提示性公告 顾康、顾小舟及其控制的企业上海小洲光电科技有限公司保证向本公司提供的信 息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏，并对其内容的真实性、 准确性和完整性依法承担法律责任。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少☑ | | --- | --- | --- | --- | | 权益变动前合计比例 | 31.36% | | | | 权益变动后合计比例 | 30.00% | | | | 本次变动是否违反已作出的承 | 是□ | 否☑ | | | 诺、意向、计划 | | | | | 是否触发强制要约收购义务 | 是□ | 否☑ | | 注：上表中"权益变动前合计比例"是以上海澳华内镜股份有限公司（以下简称"公司"） 首次公开发行股票并在科创板上市日的持股情况和总股本进行计算，"权益变动后合计比例" 根据公司当前总股本计算得出。 一、信息披露义务人及其 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

证券代码：688212 证券简称：澳华内镜 公告编号：2025-071 会议召开时间：2025 年 11 月 26 日（星期三）13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 19 日（星期三）至 11 月 25 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir@aohua.com）进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海澳华内镜股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日 发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 26 日（星期三） 13:00-14:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 上海澳华内镜股份有限公司 关于召开 2025 年第三季度业绩说明 ...

上海市通力律师事务所关于上海澳华内镜股份有限公司 2025 年第三次临时股东大会的法律意见书 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司"）的委托,指派本所茹秋乐律师、章唐乾律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《上海澳华内镜股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第三次临时股东大会（以下简称"本次股东大会"）相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表 意见,并不对本次股东大会所审议的议案内容 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-070 上海澳华内镜股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议由公司董事会召集，董事长顾康先生因工作行程冲突原因未能出席 会议，经公司半数以上董事推举，本次会议由公司董事陈鹏先生主持。本次会议 采用现场投票与网络投票相结合的方式进行表决。本次会议的召集、召开及表决 程序符合《公司法》《证券法》及《公司章程》的相关规定。 （五） 公司董事和董事会秘书的出席情况 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 14 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 186 | | --- | --- | | 普通股股东人数 | 186 | | ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - The company's performance meets expectations, with a revenue inflection point observed. In Q3 2025, the company reported revenue of 162 million yuan, a year-on-year increase of 10.37%, marking a return to positive growth for the quarter. However, the net profit attributable to the parent company was -15 million yuan, a decrease of 148.44% year-on-year, primarily due to changes in product mix affecting gross margin and a high base effect from 2024 [2][4][11]. - The new product AQ-400 is expected to enter a ramp-up phase, featuring advanced imaging technology and capabilities that could enhance the company's competitive edge in the market, particularly in tertiary hospitals [11]. - The company is focusing on expanding its overseas market presence, particularly in high-end models, with established marketing support centers in Europe and other regions, which is anticipated to drive rapid growth in international business [11]. - Future profit projections for the company are optimistic, with expected net profits of 11 million yuan, 49 million yuan, and 140 million yuan for 2025, 2026, and 2027, respectively [11]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported total revenue of 423 million yuan, a year-on-year decrease of 15.57%. The net profit attributable to the parent company was -56 million yuan, down 250.37% year-on-year. In Q3 2025, revenue was 162 million yuan, up 10.37% year-on-year, while the net profit was -15 million yuan, a decrease of 148.44% [4][11]. Product Development - The AQ-400 product features significant upgrades, including 3D imaging technology, EDOF functionality, and a high-spectral optical staining platform, which are expected to create a differentiated competitive advantage and increase market share in tertiary hospitals [11]. Market Expansion - The company is actively deepening its presence in overseas markets, with a focus on high-end products. It has made progress in market access in Europe and is expanding coverage in regions such as Brazil, South Korea, and Malaysia [11].

Group 1: Non-Metallic Building Materials - The building materials industry shows signs of structural growth that gradually outweigh environmental impacts, with Q3 2025 reports indicating a recovery in revenue and profitability for several companies [2][25] - The cement sector continues to perform well overseas, particularly in Africa, while domestic demand and prices have weakened, suggesting a potential bottoming out in 2024 [4][26] - In the consumer building materials sector, revenue growth disparities among sub-industries are widening, driven by the impacts of real estate and local debt [5][27] Group 2: Biopharmaceuticals - Huadong Medicine's industrial segment maintains steady growth, with Q3 2025 revenue of 37.28 billion yuan, up 14.95% year-on-year, and net profit of 8.94 billion yuan, up 18.43% [7][8] - The medical aesthetics business faces short-term pressure due to economic factors, with a decline in revenue for both domestic and overseas operations [8] - The company is advancing its innovative pipeline, with several clinical trials ongoing for various cancer treatments [9][33] Group 3: Power Equipment and New Energy - Haibo Sichuang, a leader in energy storage, is expected to benefit from high industry demand, with Q3 2025 revenue reaching 3.39 billion yuan, a year-on-year increase of 124.4% [10][11] - The company's profitability has improved significantly, with a gross margin of 18.64% and a net margin of 9.05% in Q3 2025 [11] - The global energy storage market is projected to grow by 40%-50% in 2026, with significant contributions from both domestic and international markets [13] Group 4: Financial Engineering - The report highlights various asset allocation strategies, with the macro-factor-based strategy yielding a return of 4.23% in 2025, outperforming other strategies [14][15] - The performance of domestic asset strategies shows a positive trend, with October returns indicating a stable investment environment [15][16] - The overall economic outlook remains cautious, with manufacturing PMI indicating a contraction, while service sector activity shows slight improvement [16]

Core Insights - The medical equipment bidding scale has shown significant growth, indicating a new round of equipment updates is expected to emerge in 2025 [1][3] Group 1: Medical Equipment Bidding Growth - In October 2025, the new equipment bidding scale showed substantial year-on-year growth: MR increased by 59.4%, CT by 81.6%, DR by 77.4%, ultrasound by 62.8%, endoscopes by 24.4%, and surgical robots by 42.7% [1] - For October 2025 alone, the month-on-month growth rates were: MR at 2.9%, CT at 49.4%, DR at 54.4%, ultrasound at 59.9%, endoscopes at 11.6%, and surgical robots at 108.9% [1] Group 2: Company Performance - In October 2025, company-specific performance showed varied results: - United Imaging's MR decreased by 5.9%, while CT increased by 74.7% - Mindray's ultrasound grew by 61.8% - Kaili's ultrasound and endoscope grew by 54.5% and 96.6% respectively - Aohua's endoscope increased by 4.8% [2] - Cumulatively for the year, United Imaging's MR grew by 46.6%, CT by 59.4%, Mindray's ultrasound by 74.1%, Kaili's ultrasound by 98.1%, Kaili's endoscope by 96.5%, and Aohua's endoscope by 19.7% [2] Group 3: Policy Impact on Market - The implementation of equipment update policies is expected to drive long-term procurement levels in the medical equipment sector [3] - A joint notice from four ministries in 2024 aims for a 25% increase in medical equipment investment by 2027 compared to 2023, enhancing high-end equipment availability [3] - The domestic market is showing signs of recovery, with increased procurement demand from medical institutions due to supportive macroeconomic policies [4] - United Imaging reported a revenue of 6.866 billion yuan in the domestic market for the first three quarters of 2025, reflecting a year-on-year growth of 23.7% [4]

Group 1 - The stock price of Aohua Endoscopy (688212) closed at 51.41 yuan on November 11, 2025, with an increase of 0.86% and a turnover rate of 1.89% [1] - The trading volume was 25,500 shares, with a total transaction amount of 130 million yuan [1] - On November 11, the net inflow of main funds was 7.1485 million yuan, accounting for 5.5% of the total transaction amount [1][3] Group 2 - Aohua Endoscopy received a government subsidy of 3.4299 million yuan on November 7, 2025, which is related to income [2][3] - The company will recognize the subsidy according to relevant accounting standards, and the final impact on the company's profit and loss will be confirmed by the annual audit [2]